Experimental Treatment for Neurofibromatosis Type 1 Earns Orphan Drug Designation in the EU
pixel2013 / Pixabay

Experimental Treatment for Neurofibromatosis Type 1 Earns Orphan Drug Designation in the EU

According to a story from BioPortfolio, the biopharmaceutical company SpringWorks Therapeutics, Inc., has recently announced that the European Commission has given the company's investigational drug candidate mirdametinib Orphan Drug designation.…

Continue Reading Experimental Treatment for Neurofibromatosis Type 1 Earns Orphan Drug Designation in the EU
Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation
Free-Photos / Pixabay

Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation

According to a story from Acrofan, the biopharmaceutical company SpringWorks Therapeutics, Inc. has recently announced the that company's experimental product candidate PD-0325901 has earned Fast Track designation from the US…

Continue Reading Potential Treatment for Neurofibromatosis Type 1 Earns Fast Track Designation
After Neurofibromatosis Type 2 Prevented her From Getting Pregnant, her Twin Offered to Serve as a Surrogate
Free-Photos / Pixabay

After Neurofibromatosis Type 2 Prevented her From Getting Pregnant, her Twin Offered to Serve as a Surrogate

According to a story from KTVZ, Jill Noe and Whitney Bliesner have always shared a special bond. They are twins, now 34 years old. Despite their closeness, they do share…

Continue Reading After Neurofibromatosis Type 2 Prevented her From Getting Pregnant, her Twin Offered to Serve as a Surrogate

New Potential Treatment for Neurofibromatosis Type 1 Given Breakthrough Therapy Designation

A new medication called selumetinib has just received Breakthrough Therapy designation by the FDA for pediatric patients diagnosed with neurofibromatosis type 1 (NF1) or inoperable pleciform neurofibromas. This therapy has…

Continue Reading New Potential Treatment for Neurofibromatosis Type 1 Given Breakthrough Therapy Designation
New Open Data Portal Will Improve Neurofibromatosis Research
Free-Photos / Pixabay

New Open Data Portal Will Improve Neurofibromatosis Research

According to a story from EurekAlert!, a collaboration of Sage Bionetworks, The Children's Tumor Foundation (CTF), and the Neurofibromatosis Therapeutic Acceleration Program (NTAP) have announced the initiation of the very…

Continue Reading New Open Data Portal Will Improve Neurofibromatosis Research
“Many Faces of NF”: Artist Highlights Tumor-Causing Genetic Disorder
mcmurryjulie / Pixabay

“Many Faces of NF”: Artist Highlights Tumor-Causing Genetic Disorder

If you haven't heard of neurofibromatosis (NF), you’re in surprisingly good company. For most of her life, Rachel Mindrup, an artist, illustrator, and Resident Assistant Professor at Creighton University, who…

Continue Reading “Many Faces of NF”: Artist Highlights Tumor-Causing Genetic Disorder
Experimental Treatment for NF-1 Gets Orphan Drug Designation
frolicsomepl / Pixabay

Experimental Treatment for NF-1 Gets Orphan Drug Designation

According to a story from BioPortfolio, the biopharmaceutical company SpringWorks Therapeutics recently announced that the US Food and Drug Administration (FDA) has given the company's experimental product PD-0325901 Orphan Drug…

Continue Reading Experimental Treatment for NF-1 Gets Orphan Drug Designation

A Man Who Set Up a Healthcare Company After Being Diagnosed with Neurofibromatosis Has Secured $3 Million Funding

  The healthcare technology company RDMD was founded by Onno Faber, who has himself been diagnosed with a rare disorder. RDMD, which describes itself as “dedicated to accelerating research” with…

Continue Reading A Man Who Set Up a Healthcare Company After Being Diagnosed with Neurofibromatosis Has Secured $3 Million Funding
The First Double Face Transplant Has Just Been Performed on a Neurofibromatosis Patient in France
Source: Pixabay

The First Double Face Transplant Has Just Been Performed on a Neurofibromatosis Patient in France

A man in France has been the first person to ever receive two face transplants, reports the BBC. After Jérôme Hamon’s first transplant was rejected he underwent a second transplant…

Continue Reading The First Double Face Transplant Has Just Been Performed on a Neurofibromatosis Patient in France
This Cancer Drug May Reduce Hearing Loss From Radiotherapy In Patients With Neurofibromatosis
RobinHiggins / Pixabay

This Cancer Drug May Reduce Hearing Loss From Radiotherapy In Patients With Neurofibromatosis

According to a story from Medical Xpress, the addition of crizotinib with radiation therapy could help reduce hearing loss associated with the treatment in patients with neurofibromatosis II. Crizotinib is…

Continue Reading This Cancer Drug May Reduce Hearing Loss From Radiotherapy In Patients With Neurofibromatosis
This Treatment for Neurofibromatosis Type 1 Just Got Orphan Drug Designation
Pixabay: https://pixabay.com/en/medic-hospital-laboratory-medical-563425/

This Treatment for Neurofibromatosis Type 1 Just Got Orphan Drug Designation

According to a story from Business Wire, selumetinib, a drug in development for the treatment for neurofibromatosis type 1, was recently granted Orphan Drug Designation by the Food and Drug…

Continue Reading This Treatment for Neurofibromatosis Type 1 Just Got Orphan Drug Designation